Nonphysiologic overexpression of amyloid-β (Aβ) precursor protein in common transgenic Aβ mouse models of Alzheimer disease likely hampers their translational potential. The novel App NL-G-F mouse incorporates a mutated knock-in, potentially presenting an improved model of Alzheimer disease for Aβ-targeting treatment trials. We aimed to establish serial small-animal PET of amyloidosis and neuroinflammation in App NL-G-F mice as a tool for therapy monitoring. Methods: App NL-G-F mice (20 homozygous and 21 heterogeneous) and 12 age-matched wild-type mice were investigated longitudinally from 2.5 to 10 mo of age with 18F-florbetaben Aβ PET and 18F-GE-180 18-kDa translocator protein (TSPO) PET. Voxelwise analysis of SUV ratio images was performed using statistical parametric mapping. All mice underwent a Morris water maze test of spatial learning after their final scan. Quantification of fibrillar Aβ and activated microglia by immunohistochemistry and biochemistry served for validation of the PET results. Results: The periaqueductal gray emerged as a suitable pseudo reference tissue for both tracers. Homozygous App NL-G-F mice had a rising SUV ratio in cortex and hippocampus for Aβ (+9.1%, +3.8%) and TSPO (+19.8%, +14.2%) PET from 2.5 to 10 mo of age (all P < 0.05), whereas heterozygous App NL-G-F mice did not show significant changes with age. Significant voxelwise clusters of Aβ deposition and microglial activation in homozygous mice appeared at 5 mo of age. Immunohistochemical and biochemical findings correlated strongly with the PET data. Water maze escape latency was significantly elevated in homozygous App NL-G-F mice compared with wild-type at 10 mo of age and was associated with high TSPO binding. Conclusion: Longitudinal PET in App NL-G-F knock-in mice enables monitoring of amyloidogenesis and neuroinflammation in homozygous mice but is insensitive to minor changes in heterozygous animals. The combination of PET with behavioral tasks in App NL-G-F treatment trials is poised to provide important insights in preclinical drug development.
Nonphysiologic overexpression of amyloid-β (Aβ) precursor protein in common transgenic Aβ mouse models of Alzheimer disease likely hampers their translational potential. The novel App NL-G-F mouse incorporates a mutated knock-in, potentially presenting an improved model of Alzheimer disease for Aβ-targeting treatment trials. We aimed to establish serial small-animal PET of amyloidosis and neuroinflammation in App NL-G-F mice as a tool for therapy monitoring. Methods: App NL-G-F mice (20 homozygous and 21 heterogeneous) and 12 age-matched wild-type mice were investigated longitudinally from 2.5 to 10 mo of age with 18F-florbetaben Aβ PET and 18F-GE-180 18-kDa translocator protein (TSPO) PET. Voxelwise analysis of SUV ratio images was performed using statistical parametric mapping. All mice underwent a Morris water maze test of spatial learning after their final scan. Quantification of fibrillar Aβ and activated microglia by immunohistochemistry and biochemistry served for validation of the PET results. Results: The periaqueductal gray emerged as a suitable pseudo reference tissue for both tracers. Homozygous App NL-G-F mice had a rising SUV ratio in cortex and hippocampus for Aβ (+9.1%, +3.8%) and TSPO (+19.8%, +14.2%) PET from 2.5 to 10 mo of age (all P < 0.05), whereas heterozygous App NL-G-F mice did not show significant changes with age. Significant voxelwise clusters of Aβ deposition and microglial activation in homozygous mice appeared at 5 mo of age. Immunohistochemical and biochemical findings correlated strongly with the PET data. Water maze escape latency was significantly elevated in homozygous App NL-G-F mice compared with wild-type at 10 mo of age and was associated with high TSPO binding. Conclusion: Longitudinal PET in App NL-G-F knock-in mice enables monitoring of amyloidogenesis and neuroinflammation in homozygous mice but is insensitive to minor changes in heterozygous animals. The combination of PET with behavioral tasks in App NL-G-F treatment trials is poised to provide important insights in preclinical drug development.
Authors: Matthias Brendel; Carola Focke; Tanja Blume; Finn Peters; Maximilian Deussing; Federico Probst; Anna Jaworska; Felix Overhoff; Nathalie Albert; Simon Lindner; Barbara von Ungern-Sternberg; Peter Bartenstein; Christian Haass; Gernot Kleinberger; Jochen Herms; Axel Rominger Journal: J Nucl Med Date: 2017-07-13 Impact factor: 10.057
Authors: Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson Journal: Nature Date: 2012-08-02 Impact factor: 49.962
Authors: Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman Journal: Cold Spring Harb Perspect Med Date: 2011-09 Impact factor: 6.915
Authors: Silvio R Meier; Stina Syvänen; Greta Hultqvist; Xiaotian T Fang; Sahar Roshanbin; Lars Lannfelt; Ulf Neumann; Dag Sehlin Journal: J Nucl Med Date: 2018-05-31 Impact factor: 10.057
Authors: Matthias Brendel; Gernot Kleinberger; Federico Probst; Anna Jaworska; Felix Overhoff; Tanja Blume; Nathalie L Albert; Janette Carlsen; Simon Lindner; Franz Josef Gildehaus; Laurence Ozmen; Marc Suárez-Calvet; Peter Bartenstein; Karlheinz Baumann; Michael Ewers; Jochen Herms; Christian Haass; Axel Rominger Journal: Front Aging Neurosci Date: 2017-01-31 Impact factor: 5.750
Authors: Ruiqing Ni; Zhenyue Chen; Xosé Luís Deán-Ben; Fabian F Voigt; Daniel Kirschenbaum; Gloria Shi; Alessia Villois; Quanyu Zhou; Alessandro Crimi; Paolo Arosio; Roger M Nitsch; K Peter R Nilsson; Adriano Aguzzi; Fritjof Helmchen; Jan Klohs; Daniel Razansky Journal: Nat Biomed Eng Date: 2022-07-14 Impact factor: 29.234
Authors: Tomás R Guilarte; Alexander N Rodichkin; Jennifer L McGlothan; Arlet Maria Acanda De La Rocha; Diana J Azzam Journal: Pharmacol Ther Date: 2021-11-27 Impact factor: 13.400
Authors: Nathalie L Albert; M Unterrainer; L Kaiser; M Brendel; F J Vettermann; A Holzgreve; P Bartenstein Journal: Eur J Nucl Med Mol Imaging Date: 2020-06-10 Impact factor: 9.236
Authors: Florian Eckenweber; Jose Medina-Luque; Tanja Blume; Christian Sacher; Gloria Biechele; Karin Wind; Maximilian Deussing; Nils Briel; Simon Lindner; Guido Boening; Barbara von Ungern-Sternberg; Marcus Unterrainer; Nathalie L Albert; Andreas Zwergal; Johannes Levin; Peter Bartenstein; Paul Cumming; Axel Rominger; Günter U Höglinger; Jochen Herms; Matthias Brendel Journal: J Neuroinflammation Date: 2020-07-13 Impact factor: 8.322
Authors: Gloria Biechele; Nicolai Franzmeier; Tanja Blume; Michael Ewers; Jose Medina Luque; Florian Eckenweber; Christian Sacher; Leonie Beyer; Francois Ruch-Rubinstein; Simon Lindner; Franz-Josef Gildehaus; Barbara von Ungern-Sternberg; Paul Cumming; Peter Bartenstein; Axel Rominger; Günter U Höglinger; Jochen Herms; Matthias Brendel Journal: J Neuroinflammation Date: 2020-12-14 Impact factor: 8.322
Authors: Aisling M Chaney; Francisco R Lopez-Picon; Sophie Serrière; Rui Wang; Daniela Bochicchio; Samuel D Webb; Matthias Vandesquille; Michael K Harte; Christina Georgiadou; Catherine Lawrence; Julie Busson; Johnny Vercouillie; Clovis Tauber; Frédéric Buron; Sylvain Routier; Tristan Reekie; Anniina Snellman; Michael Kassiou; Johanna Rokka; Karen E Davies; Juha O Rinne; Dervis A Salih; Frances A Edwards; Llwyd D Orton; Stephen R Williams; Sylvie Chalon; Hervé Boutin Journal: Theranostics Date: 2021-05-03 Impact factor: 11.556
Authors: Benjamin B Tournier; Stergios Tsartsalis; Kelly Ceyzériat; Valentina Garibotto; Philippe Millet Journal: Cells Date: 2020-08-21 Impact factor: 6.600
Authors: Michael Ewers; Gloria Biechele; Marc Suárez-Calvet; Christian Sacher; Tanja Blume; Estrella Morenas-Rodriguez; Yuetiva Deming; Laura Piccio; Carlos Cruchaga; Gernot Kleinberger; Leslie Shaw; John Q Trojanowski; Jochen Herms; Martin Dichgans; Matthias Brendel; Christian Haass; Nicolai Franzmeier Journal: EMBO Mol Med Date: 2020-08-10 Impact factor: 12.137